Operationalizing protocol differences for EADC‐ADNI manual hippocampal segmentation
Abstract
Hippocampal volumetry on magnetic resonance imaging is recognized as an Alzheimer's disease (AD) biomarker, and manual segmentation is the gold standard for measurement. However, a standard procedure is lacking. We operationalize and quantitate landmark differences to help a Delphi panel converge on a set of landmarks.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- May 23, 2013
- Source ID
- 10.1016/j.jalz.2013.03.001
Entities
People
- Alberto Redolfi
- Clifford Jack
- Craig Watson
- Eadc‐adni Working Group On The Harmonized Protocol For Manual Hippocampal Segmentation And For The Alzheimer's Disease Neuroimaging Initiative
- George Bartzokis
- Giovanni B. Frisoni
- Hilkka Soininen
- Jens C. Pruessner
- Johannes Pantel
- John G. Csernansky
- Leyla Detoledo‐morrell
- Marina Boccardi
- Martina Bocchetta
- Mony J. De Leon
- Nicolas Robitaille
- Nikolai Malykhin
- Ronald J. Killiany
- Rossana Ganzola
- Simon Duchesne
- Stephane Lehericy
Organizations
- Abbott Fund
- Alzheimer's Association
- Alzheimer's Disease Neuroimaging Initiative
- Alzheimer's Drug Discovery Foundation
- Amorfix (Canada)
- AstraZeneca
- Bayer HealthCare
- BioClinica
- Biogen
- Bristol-Myers Squibb
- Canadian Institutes of Health Research
- Chiron Corporation
- Eisai
- Eli Lilly and Company
- GE HealthCare
- Hoffmann-La Roche
- Innogenetics
- Johnson & Johnson Pharmaceutical Research and Development
- Laboratoires Servier
- Laval University
- Medpace
- Merck & Co.
- Meso Scale Diagnostics (United States)
- National Institute of Biomedical Imaging and Bioengineering
- National Institute on Aging
- National Institutes of Health
- Pfizer
- Roche (United States)
- Takeda Pharmaceutical Company
- University of Geneva
- Wyeth